KR920000754A - 환식아미드 유도체 - Google Patents

환식아미드 유도체 Download PDF

Info

Publication number
KR920000754A
KR920000754A KR1019910009534A KR910009534A KR920000754A KR 920000754 A KR920000754 A KR 920000754A KR 1019910009534 A KR1019910009534 A KR 1019910009534A KR 910009534 A KR910009534 A KR 910009534A KR 920000754 A KR920000754 A KR 920000754A
Authority
KR
South Korea
Prior art keywords
cyclic amide
dione
dihydro
pharmacologically acceptable
ethyl
Prior art date
Application number
KR1019910009534A
Other languages
English (en)
Other versions
KR940004391B1 (en
Inventor
하찌로오 스끼모도
마사히로 요오나가
노리오 가리베
요우이찌 이이무라
사또시 나가도
아쯔시 사사끼
요시하루 야마니시
히로오 오꾸라
다까시 고사사
구미 우찌꼬시
기요미 야마쯔
Original Assignee
나이또오 하루오
에자이 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나이또오 하루오, 에자이 가부시끼가이샤 filed Critical 나이또오 하루오
Publication of KR920000754A publication Critical patent/KR920000754A/ko
Application granted granted Critical
Publication of KR940004391B1 publication Critical patent/KR940004391B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

내용 없음

Description

환식아미드 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 식(Ⅰ) : R1-(CH2)n-Z의 환식 아미드 유도체 또는 그것의 약리학적 허용염. 상기식에서 R1은 치환 또는 비치환 환식 아미드화합물로부터 유도된 기이고 n은 0 또는 1 내지 10의 정수이고 Z는,
    이고 여기서 R2는 아릴, 치환아릴, 시클로알킬 또는 복소환기이고 m은 1 내지 6의 정수이고, R3은 수소원자 또는 저급알킬이고 R4는 아릴 또는 치환아릴, 시클로알킬 또는 복소환식기이고 p는 1 내지 6의 정수이고 단 환식아미드 화합물을 퀴나졸린-온 또는 퀴나졸린-디온이고 R2와 R4는 아릴 또는 치환아릴 어느것도 아니다.
  2. 제1항에 있어서, Z가 (1)인 것을 특징으로 하는 환식 아미드 유도체 또는 그것의 약리학적 허용염.
  3. 제1항에 있어서, Z가 (1)이고 R2가 페닐, 피리딜, 시클로펜틸 및 1,3-디옥산-2-일로 구성되는 군으로부터 선택되고 n이 1 또는 2이고 m이 1 또는 2인 것을 특징으로 하는 환식아미드 유도체 또는 그것의 약리학적 허용염.
  4. 제1항에 있어서, Z가 (1)이고 R2가 페닐, 피리딜, 시클로펜틸 및 1,3-디옥산-2-일로 구성되는 군으로부터 선택되고 n이 1 또는 2이고 m이 1또는 2이고 R1에 대한 환식아미드 유도체가 2H-3,4-디히드로-1,3-벤즈옥사진-2-온, 2H-3,4-디히드로-1,3-벤즈옥사진-2,4-디온, 1,2,3,4-테트라하드로-퀴나졸린-2,4-디온, 1,2,3,4-테트라하드로-퀴나졸린-2-온, 1,2,3,4-테트라하드로-피리도(3,2-d)피리미딘-2,4-디온, 1,2,3,4-테트라하드로-프레리딘-2,4-디온 및 1,2,3,4-테트라하드로-피리도(3,2-d)피리미딘-2-온으로 구성되는 군으로 부터 선택되는 것을 특징으로 하는 환식 아미드유도체 또는 그것의 약리학적 허용염.
  5. 제4항에 있어서, R1이 저급알킬 또는 저급 알콕시기로 치환되는 것을 특징으로 하는 환식 아미드유도체 또는 그것의 약리학적 허용염.
  6. 제4항에 있어서, R1이 메톡시로 치환되는 것을 특징으로 하는 환식아미드 유도체 또는 그것의 약리학적 허용염.
  7. 제1항에 있어서, Z가 (2)인 것을 특징으로 하는 환식아미드 유도체 또는 그것의 약리학적 허용염.
  8. 제1항에 있어서, Z가 (2)이고 R3가 저급알킬이고 R4가 페닐, 피리딜, 시클로펜틸 및 1,3-디옥산-2-일로부터 선택되는 것을 특징으로 하는 환식 아미드 유도체 또는 그것의 약리학적 허용염.
  9. 제1항에 있어서, 유도체가 3-(2-(1-벤질-4-피레리딜)에틸)5-메톡시-2H-3,4-디히드로-1,3-벤즈옥사딘-2-온, 3-(2-(1-(4-피리딜메틸)-4-피레리딜)에틸)-2H-3,4-디히드로-1,3-벤즈옥사딘-2-온, 3-(2-(1,3-디옥소란-2-일-메틸)-4-피레리딘)에틸)-6-메톡시-2H-3,4-디히드로-1,3-벤즈옥사딘-2-온, 3-(2-(시클로펜틸메틸-4-피레리딜)에틸-2H-3,4-디히드로-1,3-벤즈옥사딘-2,4-디온, 3-(2-(1,3-디옥소란-2-일-메틸)-4-피레리딘)에틸)-2H-3,4-디히드로-1,3-벤즈옥사딘-2,4-디온, 3-(2-(1-(1,3-디옥소란-2-일-메틸)-4-피레리딘)에틸)-5-메톡시-1,2,3,4-테트라히드로-퀴나졸린-2,4-디온, 3-(2-(1-벤질-4-피레리딜)에틸)-6-메톡시-2H-3,4-디히드로-1,3-벤즈옥사진-2-온 및 3-(2-(1-벤질-4-피레리딜)에틸)-6-메톡시-2H-3,4-디히드로-1,3-벤즈옥사진-2,4-디온, 으로 구성되는 군으로부터 선택되는 것을 특징으로 하는 환식아미드 유도체 또는 그것의 약리학적 허용염.
  10. 제1항의 환식 아미드 유도체의 약리학적 유효량 및 약리학적 허용담체를 함유하는 것을 특징으로 하는 약학적 조성물.
  11. 제1항의 유도체의 약리학적 유효량을 환자에 투여하는 것으로 이루어지는 것을 특징으로 하는 중추 콜린 기능의 불완전에 기인한 질병의 치료 및 예방방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR91009534A 1990-06-15 1991-06-10 Cyclic amide derivatives KR940004391B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15713490 1990-06-15
JP2-157134 1990-06-15

Publications (2)

Publication Number Publication Date
KR920000754A true KR920000754A (ko) 1992-01-29
KR940004391B1 KR940004391B1 (en) 1994-05-25

Family

ID=15642948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR91009534A KR940004391B1 (en) 1990-06-15 1991-06-10 Cyclic amide derivatives

Country Status (17)

Country Link
US (6) US5292735A (ko)
EP (3) EP0742216B1 (ko)
JP (2) JP2807577B2 (ko)
KR (1) KR940004391B1 (ko)
CN (1) CN1045206C (ko)
AT (3) ATE164156T1 (ko)
AU (2) AU653938B2 (ko)
CA (2) CA2044515C (ko)
DE (3) DE69130120T2 (ko)
DK (2) DK0468187T3 (ko)
ES (2) ES2113355T3 (ko)
FI (1) FI114797B (ko)
HU (2) HU216188B (ko)
NO (1) NO180540B1 (ko)
NZ (2) NZ238534A (ko)
PT (1) PT97993B (ko)
ZA (1) ZA914423B (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
FR2677019B1 (fr) * 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
US5462934A (en) * 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
CA2134077C (en) * 1992-04-23 2002-05-21 Thaddeus R. Nieduzak 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
EP0567090B1 (en) * 1992-04-24 2000-07-26 Takeda Chemical Industries, Ltd. Benzoxazepine derivatives as cholinesterase inhibitors
US5624926A (en) * 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
CA2167198C (en) * 1993-07-15 1999-03-16 Kunio Satake Benzylaminoquinuclidines
EP0637586B1 (en) * 1993-08-05 1999-06-02 HOECHST MARION ROUSSEL, Inc. 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)-benzofuran-7-carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors
FR2750991A1 (fr) * 1996-07-12 1998-01-16 Pf Medicament Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament
FR2752732B1 (fr) 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
DE19708846A1 (de) * 1997-03-05 1998-09-17 Gruenenthal Gmbh Neue Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
KR100639543B1 (ko) 1998-09-30 2006-10-31 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US7794761B2 (en) * 2000-04-13 2010-09-14 Seroctin Research & Technology, Inc. Methods for inducing anti-anxiety and calming effects in animals and humans
US20040192669A1 (en) * 2000-04-13 2004-09-30 Rosenfeld Mark J. Novel compounds for use in weight loss and appetite suppression in humans
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
US7524877B2 (en) 2003-11-20 2009-04-28 Seroctin Research & Technology, Inc. Compounds for use in weight loss and appetite suppression in humans
GB0507695D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
WO2007107846A1 (en) * 2006-03-20 2007-09-27 Council Of Scientific And Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
HUE042335T2 (hu) 2014-10-14 2019-06-28 Vitae Pharmaceuticals Inc ROR-gamma dihidropirrolopiridin inhibitorai
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
MX2017015752A (es) 2015-06-19 2018-04-13 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
CN108623610B (zh) * 2018-06-04 2020-08-11 中国科学院化学研究所 一种氮杂*酮化合物及其制备方法
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
CN108658887B (zh) * 2018-06-20 2022-04-05 中南大学 苯并[d][1,3]噁嗪-2,4(1H)-二酮衍生物及其合成方法和用途
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3494932A (en) * 1967-06-26 1970-02-10 American Cyanamid Co Aminoalkyl substituted aryl hydantoins
ZA76475B (en) * 1975-03-10 1977-08-31 Ciba Geigy Ag Indolyalkylpiperidines
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
DE2639718A1 (de) * 1976-09-03 1978-03-16 Thomae Gmbh Dr K Neue phenylaethylamine
JPS5344574A (en) * 1976-10-01 1978-04-21 Yoshitomi Pharmaceut Ind Ltd Hydantoin derivatives
US4174443A (en) * 1977-12-30 1979-11-13 Gaf Corporation Aza-bis-lactams
GR71865B (ko) * 1978-03-20 1983-07-07 Ciba Geigy
IL57005A (en) * 1978-04-11 1983-11-30 Smith Kline French Lab Process for the preparation of 2-amino pyrimid-4-one derivatives and novel 2-nitroaminopyrimid-4-ones as intermediates therefor
JPS54160371A (en) * 1978-06-02 1979-12-19 Kyowa Hakko Kogyo Co Ltd Novel piperidine derivative and hypotensive agents comprising it
JPS5524155A (en) * 1978-08-10 1980-02-21 Yoshitomi Pharmaceut Ind Ltd Piperidine derivative having heterocyclic ring at 4-position
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
JPS5576872A (en) * 1978-12-06 1980-06-10 Yoshitomi Pharmaceut Ind Ltd Imidazolidinone derivative
US4521418A (en) * 1979-02-21 1985-06-04 Smith Kline & French Laboratories Limited Guanidinothiazolyl derivatives
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
DE2924064A1 (de) * 1979-06-15 1980-12-18 Boehringer Sohn Ingelheim Neue 1- eckige klammer auf n-phenylalkyl-piperidyl-(4) eckige klammer zu -imidazolidinone-(2) und verfahren zu ihrer herstellung
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JPS5924990B2 (ja) * 1979-11-21 1984-06-13 協和醗酵工業株式会社 新規なピペリジン誘導体
EP0029707B1 (en) * 1979-11-21 1984-02-01 Kyowa Hakko Kogyo Co., Ltd Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
JPS6043064B2 (ja) * 1979-11-28 1985-09-26 ウェルファイド株式会社 新規イソオキサゾ−ル誘導体
JPS56142280A (en) * 1980-04-08 1981-11-06 Yoshitomi Pharmaceut Ind Ltd Piperidine compound
DE3026534A1 (de) * 1980-07-12 1982-03-18 C.H. Boehringer Sohn, 6507 Ingelheim 3,1-benzoxazin-2-one, ihre herstellung und verwendung
JPS5753481A (en) * 1980-09-17 1982-03-30 Yoshitomi Pharmaceut Ind Ltd 4-hydrouracil-piperidines
ZW21281A1 (en) * 1980-10-01 1981-11-18 Smith Kline French Lab Amine derivatives
US4352933A (en) * 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
JPS57212180A (en) * 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
US4420615A (en) * 1981-08-24 1983-12-13 Merck & Co., Inc. Substituted pyridopyrimidines as gastric secretion inhibitors
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
ZA836995B (en) * 1982-09-30 1984-05-30 Robins Co Inc A H Fused arpmatic oxazepinones and sulfur analogs thereof in a method of counteracting histamine
DE3382028D1 (de) * 1982-09-30 1991-01-10 Robins Co Inc A H Kondensierte aromatische oxazepinone und sulphuranaloge, ihrer herstellung und verwendung als histamin-antagonist.
US4495194A (en) * 1982-11-12 1985-01-22 Mead Johnson & Company Antihypertensive isoindole derivatives
US4600758A (en) * 1982-11-12 1986-07-15 Mead Johnson & Company Isoindole derivatives
JPS5995265A (ja) * 1982-11-19 1984-06-01 Yoshitomi Pharmaceut Ind Ltd ピロリジン誘導体
US4505911A (en) * 1983-10-13 1985-03-19 Mead Johnson & Company Isoindole diuretic derivatives, compositions and use
JPS60169470A (ja) * 1984-02-10 1985-09-02 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
AR241161A1 (es) * 1984-07-30 1991-12-30 Merrelll Dow Pharmaceuticals I "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida"
EP0204349A3 (de) * 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
GB8609331D0 (en) * 1986-04-16 1986-05-21 Pfizer Ltd Anti-arrythmia agents
DE3631013A1 (de) * 1986-09-12 1988-03-24 Thomae Gmbh Dr K Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3640641A1 (de) * 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
CA1305148C (en) * 1987-08-19 1992-07-14 Hiromu Matsumura Carbamoylpyrrolidone derivatives and drugs for senile dementia
EP0312283A3 (en) * 1987-10-14 1990-05-09 Merck & Co. Inc. Di-or tripeptide renin inhibitors containing lactam conformational restrictions in achpa
DE3738844A1 (de) * 1987-11-16 1989-05-24 Merck Patent Gmbh Analgetikum
JP2699511B2 (ja) * 1988-01-29 1998-01-19 武田薬品工業株式会社 置換アミン類
FI892362A (fi) * 1988-06-01 1989-12-02 Eisai Co Ltd Buten- eller propensyraderivat.
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
FR2636065B1 (fr) * 1988-09-08 1993-05-07 Fabre Sa Pierre Nouveaux derives de dihydro-2,3 arylacoylaminoalcoyl-3 4h-benzoxazine-1,3 ones-4, leur preparation et leur application en tant que medicaments utiles en therapeutique
US4910302A (en) * 1988-12-19 1990-03-20 American Home Products Corporation Psychotropic polycyclic imides
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
JPH02193992A (ja) * 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
IL93473A0 (en) * 1989-02-28 1990-11-29 Pfizer Antiinflammatory benzoxazolones
JP2747013B2 (ja) * 1989-05-19 1998-05-06 エーザイ株式会社 ブテン酸又はプロペン酸誘導体
JP2725378B2 (ja) * 1989-05-29 1998-03-11 武田薬品工業株式会社 カルバミド酸エステル誘導体
KR927002347A (ko) * 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
TW197442B (ko) * 1990-02-08 1993-01-01 Pfizer
DK37790A (da) * 1990-02-13 1991-08-14 Novo Nordisk As Indolderivater, deres fremstilling og anvendelse
FR2660657B1 (fr) * 1990-04-09 1993-05-07 Adir Nouveaux derives du 3-aminochromane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
CA2124306C (en) * 1993-05-26 2004-04-06 Masami Muraoka Quinazolinone derivatives

Also Published As

Publication number Publication date
ATE170517T1 (de) 1998-09-15
NZ272015A (en) 1999-07-29
ES2123858T3 (es) 1999-01-16
NO912252A (no) 1991-12-16
CN1045206C (zh) 1999-09-22
FI912851A (fi) 1991-12-16
ZA914423B (en) 1992-03-25
EP0742216A3 (en) 1997-05-28
JP2807577B2 (ja) 1998-10-08
CA2175502C (en) 2001-07-10
US5504088A (en) 1996-04-02
CN1057262A (zh) 1991-12-25
NZ238534A (en) 1995-07-26
JPH0899974A (ja) 1996-04-16
US5292735A (en) 1994-03-08
ES2113355T3 (es) 1998-05-01
DE69129090D1 (de) 1998-04-23
US5521182A (en) 1996-05-28
AU653938B2 (en) 1994-10-20
AU680704B2 (en) 1997-08-07
DK0468187T3 (da) 1999-01-11
FI114797B (fi) 2004-12-31
DE69130120D1 (de) 1998-10-08
CA2044515A1 (en) 1991-12-16
EP0468187A3 (en) 1992-04-15
EP0677516B1 (en) 1998-09-02
HUT61742A (en) 1993-03-01
KR940004391B1 (en) 1994-05-25
AU1024695A (en) 1995-03-30
DE69132827T2 (de) 2002-06-27
PT97993A (pt) 1992-03-31
EP0742216A2 (en) 1996-11-13
EP0677516A1 (en) 1995-10-18
NO180540C (no) 1997-05-07
CA2044515C (en) 1997-05-20
JPH04235161A (ja) 1992-08-24
DE69132827D1 (de) 2002-01-03
NO180540B1 (no) 1997-05-26
EP0468187A2 (en) 1992-01-29
NO180540B (no) 1997-01-27
DE69130120T2 (de) 1999-02-18
ATE209198T1 (de) 2001-12-15
US5620976A (en) 1997-04-15
HU911986D0 (en) 1991-12-30
DK0677516T3 (da) 1999-06-07
EP0468187B1 (en) 1998-03-18
JP3224187B2 (ja) 2001-10-29
CA2175502A1 (en) 1991-12-16
ATE164156T1 (de) 1998-04-15
NO912252D0 (no) 1991-06-12
HU211895A9 (en) 1995-12-28
HU216188B (hu) 1999-05-28
AU7813691A (en) 1991-12-19
DE69129090T2 (de) 1998-08-06
PT97993B (pt) 1998-11-30
FI912851A0 (fi) 1991-06-13
EP0742216B1 (en) 2001-11-21
US5654308A (en) 1997-08-05
US5919778A (en) 1999-07-06

Similar Documents

Publication Publication Date Title
KR920000754A (ko) 환식아미드 유도체
KR930007904A (ko) 방향족 아미딘 유도체 및 이의 염
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
NO171786C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
FR2663029B1 (fr) Derives de benzothiazole, leur preparation et les medicaments les contenant.
KR920012100A (ko) 비스포스폰산 유도체, 이의 제조 및 용도
FR2678619B1 (fr) Derives de 1,2,4-thiadiazolo[3,4-b]benzothiazole, leur preparation et les medicaments les contenant.
ATE266402T1 (de) Okulares hypotonikum
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
ES2064681T3 (es) Nuevos derivados de tioformamida.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110421

Year of fee payment: 18

EXPY Expiration of term